Search

Your search keyword '"Allaire, Manon"' showing total 310 results

Search Constraints

Start Over You searched for: Author "Allaire, Manon" Remove constraint Author: "Allaire, Manon"
310 results on '"Allaire, Manon"'

Search Results

1. SAT-129 Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

3. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma

4. International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendations

5. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

8. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

9. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

11. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

14. FRI-456 Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before selective intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment

15. THU-466 Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort

16. THU-458 No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC

17. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

18. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management

19. TOP-552 Oncogenic beta-catenin is using CD155 as a molecular actor to corrupt immunosurveillance of cold HCC

22. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

23. French guidelines on TIPS: Indications and modalities.

27. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

28. No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC.

32. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab

41. The epidemiology of Budd–Chiari syndrome in France

42. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

43. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma

44. Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab

45. Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

46. Presence of esophageal varices regardless their size is associated with overall survival in patients with advanced HCC treated with Atezolizumab/Bevacizumab

47. Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort

50. Sub-optimal global public health policies and strategies to combat hepatocellular carcinoma

Catalog

Books, media, physical & digital resources